Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRI
Biofrontera
$1.16
-12.1%		$1.31
$0.55
▼
$1.66
$19.60M0.83792,719 shs917,799 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.18
+12.7%		$0.17
$0.14
▼
$0.42
$5.01M0.44,428 shs47,612 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$2.24
+1.4%		$2.19
$1.81
▼
$12.37
$18.22M0.4730,399 shs16,706 shs
Medicure Inc. stock logo
MCUJF
Medicure
$1.90
$1.20
$0.67
▼
$1.93
$19.83M1.1515,151 shs10,320 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRI
Biofrontera
0.00%-14.84%-10.81%+22.22%+46.67%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00%-4.94%-10.22%-14.95%-42.71%
Lipocine Inc. stock logo
LPCN
Lipocine
0.00%-2.64%+5.74%-3.49%-23.26%
Medicure Inc. stock logo
MCUJF
Medicure
0.00%+2.15%+98.00%+181.65%+133.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRI
Biofrontera
$1.16
-12.1%		$1.31
$0.55
▼
$1.66
$19.60M0.83792,719 shs917,799 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.18
+12.7%		$0.17
$0.14
▼
$0.42
$5.01M0.44,428 shs47,612 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$2.24
+1.4%		$2.19
$1.81
▼
$12.37
$18.22M0.4730,399 shs16,706 shs
Medicure Inc. stock logo
MCUJF
Medicure
$1.90
$1.20
$0.67
▼
$1.93
$19.83M1.1515,151 shs10,320 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRI
Biofrontera
0.00%-14.84%-10.81%+22.22%+46.67%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00%-4.94%-10.22%-14.95%-42.71%
Lipocine Inc. stock logo
LPCN
Lipocine
0.00%-2.64%+5.74%-3.49%-23.26%
Medicure Inc. stock logo
MCUJF
Medicure
0.00%+2.15%+98.00%+181.65%+133.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera Inc. stock logo
BFRI
Biofrontera
2.00
HoldN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00
N/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
1.50
Reduce$4.0078.57% Upside
Medicure Inc. stock logo
MCUJF
Medicure
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INBP, MCUJF, BFRI, and LPCN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$4.00
9/3/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/19/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/3/2026
Biofrontera Inc. stock logo
BFRI
Biofrontera
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/15/2026
Biofrontera Inc. stock logo
BFRI
Biofrontera
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/3/2026
Biofrontera Inc. stock logo
BFRI
Biofrontera
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/29/2026
Biofrontera Inc. stock logo
BFRI
Biofrontera
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera Inc. stock logo
BFRI
Biofrontera
$41.71M0.41N/AN/A$0.90 per share1.29
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$54.35M0.10$0.08 per share2.41$0.66 per share0.28
Lipocine Inc. stock logo
LPCN
Lipocine
$1.98M9.32N/AN/A$2.61 per share0.86
Medicure Inc. stock logo
MCUJF
Medicure
$20.65M0.96N/AN/A$0.89 per share2.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$10.54M-$0.45N/AN/AN/A-13.78%-145.81%-31.30%11/11/2026 (Estimated)
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$810K-$0.07N/AN/AN/A-3.43%-8.32%-6.57%N/A
Lipocine Inc. stock logo
LPCN
Lipocine
-$9.63M-$1.79N/AN/AN/A-755.39%-64.75%-57.62%11/5/2026 (Estimated)
Medicure Inc. stock logo
MCUJF
Medicure
-$5.08M-$0.51N/AN/AN/A-23.14%-54.55%-30.42%11/19/2026 (Estimated)

Latest INBP, MCUJF, BFRI, and LPCN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Medicure Inc. stock logo
MCUJF
Medicure
-$0.0474-$0.10-$0.0526-$0.10$2.45 million$5.36 million
8/13/2026Q2 2026
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$0.1050-$0.05+$0.0550-$0.05$9.50 million$12.00 million
8/4/2026Q2 2026
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.40-$0.32+$0.08-$0.32$0.21 million$0.19 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera Inc. stock logo
BFRI
Biofrontera
N/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
Medicure Inc. stock logo
MCUJF
Medicure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera Inc. stock logo
BFRI
Biofrontera
0.78
1.18
1.08
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A
3.25
1.78
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
11.48
11.48
Medicure Inc. stock logo
MCUJF
Medicure
0.02
0.97
0.64

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera Inc. stock logo
BFRI
Biofrontera
10.08%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
25.25%
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%
Medicure Inc. stock logo
MCUJF
Medicure
N/A

Insider Ownership

CompanyInsider Ownership
Biofrontera Inc. stock logo
BFRI
Biofrontera
8.10%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
67.40%
Lipocine Inc. stock logo
LPCN
Lipocine
4.69%
Medicure Inc. stock logo
MCUJF
Medicure
12.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera Inc. stock logo
BFRI
Biofrontera
9414.85 million13.65 millionNo Data
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
15330.98 million10.10 millionNot Optionable
Lipocine Inc. stock logo
LPCN
Lipocine
148.24 million7.86 millionNo Data
Medicure Inc. stock logo
MCUJF
Medicure
N/A10.44 million9.09 millionNot Optionable

Recent News About These Companies

Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress
September 8, 2026  |  accessnewswire.comA
Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
August 14, 2026  |  accessnewswire.comA
Medicure Announces CFO Change
July 3, 2026  |  accessnewswire.comA
Medicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...
May 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/medicure-inc-mcujf-q1-2026-210021888.html
Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
May 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68566676-medicure-inc-medicure-reports-financial-results-for-quarter-ended-march-31-2026-and-schedules-may-25-2026-conference-call-200.htm
Medicure Announces AGM Results and Appointment of New Director
May 21, 2026  |  accessnewswire.comA
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
May 21, 2026  |  accessnewswire.comA
Medicure Inc (MCUJF) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Rising Losses
April 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/medicure-inc-mcujf-q4-2025-070228399.html
Medicure Announces Resignation of President and Chief Operating Officer
April 17, 2026  |  accessnewswire.comA
Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended September 30, 2025
November 20, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-11/67026016-medicure-inc-medicure-reports-financial-results-for-quarter-ended-september-30-2025-200.htm
Medicure Reports Financial Results for Quarter Ended September 30, 2025
November 19, 2025  |  accessnewswire.comA
Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025
November 13, 2025  |  accessnewswire.comA
Medicure Reports Financial Results for Quarter Ended June 30, 2025
August 20, 2025  |  accessnewswire.comA
Medicure to Present Financial Results on August 21, 2025 Call at 8:30 am ET for Quarter Ended June 30, 2025
August 18, 2025  |  accessnewswire.comA
Medicure Completes Acquisition of West Olympia Pharmacy
June 17, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/medicure-completes-acquisition-of-west-olympia-pharmacy?utm_source=marketbeat.com&utm_medium=referral
Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy
June 17, 2025  |  accessnewswire.comA
Medicure reports stable intangible assets in Q1 filing
May 23, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/medicure-reports-stable-intangible-assets-in-q1-filing-93CH-4058294
Medicure: Q1 Earnings Snapshot
May 21, 2025  |  michigansthumb.comM
Medicure Reports Financial Results for Quarter Ended March 31, 2025 and Annual General Meeting Director Election Results
May 21, 2025  |  accessnewswire.comA
Medicure Inc. (MCUJF) Q4 2024 Earnings Call Transcript
April 30, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4779561-medicure-inc-mcujf-q4-2024-earnings-call-transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRI

$1.16 -0.16 (-12.12%)
As of 04:00 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Integrated BioPharma stock logo

Integrated BioPharma OTCMKTS:INBP

$0.18 +0.02 (+12.69%)
As of 02:56 PM Eastern

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Lipocine stock logo

Lipocine NASDAQ:LPCN

$2.24 +0.03 (+1.36%)
As of 04:00 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Medicure stock logo

Medicure OTCMKTS:MCUJF

$1.90 0.00 (0.00%)
As of 02:46 PM Eastern

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas